<DOC>
	<DOCNO>NCT00562484</DOCNO>
	<brief_summary>This study ass Efficacy , Safety Tolerability profile CSL 's Influenza Vaccine administer intramuscularly laboratory-confirmed influenza illness population define risk severe complication follow influenza infection .</brief_summary>
	<brief_title>A Study Efficacy , Safety Tolerability Profile CSL Limited 's Influenza Virus Vaccine ( CSL 's IVV ) Administered Intramuscularly Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female age ≥ 18 &lt; 65 year time vaccination Non pregnant/ non lactate female Hypersensitivity influenza vaccine allergy component Study Vaccines Vaccination influenza previous 6 month Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality Known history GuillainBarré Syndrome ; Clinical sign active infection and/or oral temperature ≥ 37.8 oC . History neurological disorder seizure Confirmed suspect immunosuppressive condition previously diagnose immunodeficiency disorder Current recent immunosuppressive immunomodulative therapy , include systemic corticosteroid Administration immunoglobulins and/or blood product ; Participation clinical trial use investigational compound ; Vaccination register vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior ; Participants indicate receive influenza vaccine annual basis accord local public health recommendation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>